Sven Marcel Stefan

Dr. Sven Marcel Stefan

Department of Pathology, University of Oslo, Oslo, Norway
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2018 in Medicinal Research Reviews
Verified
Journal Article
Open access
PDF file
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan
MWMichael Wiese
Michael Wiese
Multidrug resistance‐associated protein 1 (MRP1, ABCC1) is an ATP‐binding cassette (ABC) transport protein. This efflux pump uses the energy of ATP hydrolysis to export structurally diverse antineoplastic agents in human cancers. The upregulation of MRP1 (either inherent or acquired) is one major reason for the occurrence of the phenomenon called multidrug resistance (MDR). MDR is characterized by a reduced outcome of chemotherapy due to the active intracellular clearance of cytostatic drugs below the necessary effect concentration. Much effort has been made to overcome MDR, which implied high‐throughput screenings of already known pharmacological and natural compounds, modification of intrinsic substrates, as well as design and synthesis of new inhibitors. This review is meant not only to summarize the most recent results over the past 10 years, but also to highlight major achievements regarding reversal of MRP1‐mediated MDR, from the time of its discovery until today. The focus lies on small‐molecule compounds that feature either direct MRP1 inhibition/transport blockage, toxicity against MRP1‐overexpressing cells, inhibition/modification of intracellular processes necessary for MRP1 function, or modification of MRP1‐related metabolic and genomic mechanisms. Considering all aspects, this review might be useful to (re)consider possible strategies to overcome MRP1‐mediated MDR. Furthermore, it may be the basis for developing new, even better, highly potent, less toxic, and selective (as well as broad‐spectrum) MRP1 inhibitors that will enter clinical evaluations in different malignancies and finally conduce to overcome MDR in general.

18 June 2012 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
CACelso Almeida
Celso Almeida
YHYasmin Hemberger
Yasmin Hemberger
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan
SBSarah Bouhired
Sarah Bouhired
LNLavanya Natesan
Lavanya Natesan
GKGabriele König
Gabriele König


13 September 2019 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan

17 March 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan
KSKatja Stefan
Katja Stefan
MWMichael Wiese
Michael Wiese

1 February 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KSKatja Silbermann
Katja Silbermann
CSChetan P. Shah
Chetan P. Shah
NSNiteshkumar U. Sahu
Niteshkumar U. Sahu
KJKapil Juvale
Kapil Juvale
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan
MWMichael Wiese
Michael Wiese